Collegium: Use Pain Cash Flow to Back an ADHD Re-rating — Buy for a 50% Upside
Collegium (COLL) is funding an aggressive push into ADHD with cash-generative pain assets. The balance sheet and free cash flow make the $650M AZSTARYS deal immediately accretive; at current prices the stock trades cheaply versus its guidance-driven profitability. We see a clear path to a re-rating toward $50 over the next 180 trading days if integ…